Abivax SA (ABVX)
113.39
-0.91
(-0.80%)
USD |
NASDAQ |
Aug 28, 16:00
113.39
0.00 (0.00%)
After-Hours: 20:00
Abivax Debt to Equity Ratio : 0.0796 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.0796 |
| December 31, 2025 | 0.0705 |
| September 30, 2025 | 0.1447 |
| Date | Value |
|---|---|
| June 30, 2025 | -1.752 |
| March 31, 2025 | -14.04 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Poxel SA | -- |
| OSE Immunotherapeutics SA | -- |
| Cogent Biosciences, Inc. | 0.4588 |
| Compass Pathways Plc | 0.6462 |
| Vera Therapeutics, Inc. | 0.1845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 630.42M |
| Total Liabilities (Quarterly) | 135.44M |
| Shareholders Equity (Quarterly) | 494.98M |
| Current Ratio | 8.247 |
| Net Debt Paydown Yield | 0.09% |